

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

SK-MEL-30

RRID:CVCL_0039

Type: Cell Line

Proper Citation

RRID:CVCL_0039

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0039

Proper Citation: RRID:CVCL_0039

Description: Cell line SK-MEL-30 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cutaneous melanoma

Defining Citation: [PMID:978138](#), [PMID:1067619](#), [PMID:1716514](#), [PMID:3081645](#), [PMID:3473501](#), [PMID:3518877](#), [PMID:6864164](#), [PMID:6933476](#), [PMID:7175440](#), [PMID:7509835](#), [PMID:9598804](#), [PMID:10766161](#), [PMID:11668190](#), [PMID:15009714](#), [PMID:16957166](#), [PMID:20164919](#), [PMID:21725359](#), [PMID:22460905](#), [PMID:24576830](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-30

Synonyms: SK-Mel-30, SK Mel 30, SKMEL-30, Sk Mel30, SKMEL30, AW-Mel

Cross References: BTO:BTO_0002133, CLO:CLO_0009045, EFO:EFO_0006488, CLDB:cl4323, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:465,

BioSample:SAMN03473251, BioSample:SAMN10988313, cancercellines:CVCL_0039, Cell_Model_Passport:SIDM00392, ChEMBL-Cells:ChEMBL3308128, ChEMBL-Targets:ChEMBL1075577, Cosmic:706090, Cosmic:721825, Cosmic:851035, Cosmic:888061, Cosmic:888834, Cosmic:909726, Cosmic:933128, Cosmic:1022283, Cosmic:1060425, Cosmic:1669146, Cosmic-CLP:909726, DepMap:ACH-000810, DSMZ:ACC-151, DSMZCellDive:ACC-151, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909726, GEO:GSM784510, GEO:GSM887586, GEO:GSM888669, GEO:GSM1670441, GEO:GSM7701406, GEO:GSM7701407, IARC_TP53:27239, LiGeA:CCL_671, LINCS_LDP:LCL-1257, PharmacDB:SKMEL30_1398_2019, PRIDE:PXD030304, Progenetix:CVCL_0039, PubChem_Cell_line:CVCL_0039, Wikidata:Q54954059

ID: CVCL_0039

Record Creation Time: 20220427T221546+0000

Record Last Update: 20260913T010044+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-30.

No alerts have been found for SK-MEL-30.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jiao Y, et al. (2026) A Plasmonic "Lid-Off" Nanoplatfrom for Spatiotemporally Controlled PA/NIR-II Dual-Modal Imaging and Cuproptosis-Based Synergistic Photothermal and Chemodynamic Therapy. *Small* (Weinheim an der Bergstrasse, Germany), 22(37), e73776.

Wilson HP, et al. (2026) Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma. *Pigment cell & melanoma research*, 39(3), e70090.

Lahmar A, et al. (2026) Ulvan from *Ulva lactuca* Promotes Keratinocyte Migration, Adhesion, and Photoprotection Against UVB Damage. *Marine biotechnology* (New York, N.Y.), 28(3).

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. *Cancer cell*, 43(5), 823.

Angeli C, et al. (2025) High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma. *Journal of experimental & clinical cancer research* : CR, 44(1), 278.

Waddell A, et al. (2024) p300 KAT Regulates SOX10 Stability and Function in Human Melanoma. *Cancer research communications*, 4(8), 1894.

Ran XB, et al. (2023) Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy. *Cancer research*, 83(6), 922.

Cai W, et al. (2022) A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma. *Cancer research*, 82(14), 2625.

Su W, et al. (2022) ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. *Molecular cell*, 82(13), 2443.

Zhu J, et al. (2019) Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation. *Cell metabolism*, 30(5), 865.